Tiantian Zhang

Dr. Tiantian Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2019 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JXJingmei Xie
Jingmei Xie
NWNing Wan
Ning Wan
ZLZhuoru Liang
Zhuoru Liang
TZTiantian Zhang
Tiantian Zhang
JJJie Jiang
Jie Jiang
Ixazomib, as a proteasome inhibitor, inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome. Based on the TOURMALINE-MM1 study, ixazomib was proved by the FDA as the orphan drug in November 2015. With a promising effect in prolonging the progression-free survival compared with placebo treatment (median: 20.6 versus 14.7 months), it was the first oral compound combined with lenalidomide and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) who have received at least one prior therapy. The main adverse events include low-grade hematological, digestive, or cutaneous events, which were manageable with care. Overall, ixazomib demonstrated favorable safety profile. Ongoing trials are conducted to define its place in first-line, maintenance, and relapse therapies. In this review, we summarized the clinical pharmacology, efficacy, tolerability, safety, and cost-effectiveness of ixazomib.

1 July 2019 in Oral Oncology
Verified
Journal Article
Closed access
XCXudong Chen
Xudong Chen
WLWeiting Liang
Weiting Liang
NWNing Wan
Ning Wan
LZLi Zhang
Li Zhang
YYYunpeng Yang
Yunpeng Yang
TZTiantian Zhang
Tiantian Zhang